NCT00620269 - Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III | Biotech Hunter

Enrollment

212

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Lung CancerNSCLC

Interventions

DRUG

Erlotinib

Erlotinib 150 mg p.o. daily x21 days every 3 weeks

DRUG

Induction or consolidation IP chemotherapy

Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles

DRUG

CCRT with IP chemotherapy (Irinotecan + Cisplatin)

Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 \& 8 every 3 weeks X 2 cycles

RADIATION

CCRT

CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)

Trial Locations (1)

RECRUITING

National Cancer Center, Korea, Goyang-si